COSCIENS Biopharma Files 20-F, Details 2024 Financials
Ticker: CSCIF · Form: 20-F · Filed: Apr 9, 2025 · CIK: 1113423
Sentiment: neutral
Topics: 20-F, annual-report, biopharma, financials
TL;DR
COSCIENS Biopharma (fka Aeterna Zentaris) dropped its 20-F, check the 2024 financials.
AI Summary
COSCIENS Biopharma Inc. filed its 20-F report for the fiscal year ending December 31, 2024. The company, formerly known as Aeterna Zentaris Inc., is in the pharmaceutical preparations industry. The filing includes financial data for the years ending December 31, 2021, 2022, and 2023, detailing issued capital, contributed surplus, retained earnings, and accumulated other comprehensive income.
Why It Matters
This filing provides investors with a comprehensive overview of COSCIENS Biopharma's financial health and performance for the past fiscal year, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a biopharma company, COSCIENS faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.
Key Numbers
- 2024-12-31 — Fiscal Year End (The primary reporting period covered by the 20-F filing.)
- 2023-12-31 — Previous Fiscal Year End (Provides comparative financial data.)
- 2022-12-31 — Prior Fiscal Year End (Provides further comparative financial data.)
- 2021-12-31 — Prior Fiscal Year End (Provides historical financial data.)
Key Players & Entities
- COSCIENS Biopharma Inc. (company) — Filer of the 20-F report
- Aeterna Zentaris Inc. (company) — Former name of COSCIENS Biopharma Inc.
- 2024-12-31 (date) — Fiscal year end for the reported period
- 2023-12-31 (date) — Previous fiscal year end
- 2022-12-31 (date) — Fiscal year end prior
- 2021-12-31 (date) — Fiscal year end prior
FAQ
What is the primary business of COSCIENS Biopharma Inc.?
COSCIENS Biopharma Inc. is engaged in the pharmaceutical preparations industry, as indicated by its Standard Industrial Classification code [2834].
What was COSCIENS Biopharma Inc. previously known as?
COSCIENS Biopharma Inc. was formerly known as Aeterna Zentaris Inc., with a name change date of June 17, 2004.
What period does this 20-F filing cover?
This 20-F filing covers the fiscal year ending December 31, 2024.
What financial details are provided for the fiscal years 2021-2023?
The filing provides details on issued capital, contributed surplus, retained earnings, and accumulated other comprehensive income for the fiscal years ending December 31, 2021, 2022, and 2023.
Where is COSCIENS Biopharma Inc.'s business address listed?
The business address is listed as C/O NORTON ROSE FULBRIGHT CANADA LLP, 222 BAY STREET, SUITE 3000, PO BOX 53, TORONTO, A6, M5K 1E7.
Filing Details
This Form 20-F (Form 20-F) was filed with the SEC on April 9, 2025 regarding COSCIENS Biopharma Inc. (CSCIF).